The effect of galectin-3 genetic variants on the susceptibility and prognosis of gliomas in a Chinese population

• Published in: Neuroscience letters 2012-06, Vol.518 (1), p.1-4
• Main Authors: Chen, Hong-jie, Zheng, Zhao-cong, Yuan, Bang-qing, Liu, Zheng, Jing, Junjie, Wang, Shou-Sen
• Format: Article
• Language: English
• Subjects: Adenylate cyclase; Adult; Asian Continental Ancestry Group - genetics; Brain tumors; Female; Galectin 3 - analysis; Galectin 3 - genetics; Galectin-3; Gene; Gene frequency; Gene polymorphism; Genetic Predisposition to Disease; Genotype; Glioma; Glioma - diagnosis; Glioma - genetics; Glioma - mortality; Gliomas; Humans; Male; Middle Aged; Neoplasm Grading; Nervous system; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Single-nucleotide polymorphism; Survival; Susceptibility; Tumors
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2012.02.065

The genotype distribution at galectin-3 +292 was significantly different between gliomas patient and control groups. The A/A genotype of galectin-3 +292 represented a higher risk factor and shorter overall survival period than AC+CC genotype. The A/A genotype of galectin-3 +292 represented a shorter mean overall survival period than AC+CC genotype. The aim of this study is to explore the association between the polymorphisms of galectin-3 gene and clinico-pathological characteristics and prognosis of gliomas. We enrolled 190 histologically diagnosed gliomas and 210 healthy controls in this study. Two genetic variants at galectin-3 single nucleotide polymorphism (SNP) sites (galectin-3 +191 A>C and +292 A>C) were determined. We found that the A/A genotype at galectin-3 gene +292 A>C was significantly more prevalent in gliomas patient than in controls (42.1% vs. 29.0%, P=0.021); the A allele frequency was markedly higher in gliomas subjects than in controls (61.8% vs. 45.0%, P=0.008). There was a markedly higher prevalence of AA carriers in high-grade subgroup than in low-grade subgroup (50.5% vs. 31.8%, P=0.012). The Kaplan–Meier analyses showed that the gliomas patients carrying AA genotype of galectin-3 gene +292 A>C had marked shorter overall survival period than those did not (AA vs. AC+CC, 22.2±3.8 months vs. 38.3 months±7.9; P=0.04). The SNPs at +191 A>C of galectin-3 gene did not show positive association with clinico-pathological characteristics and prognosis of gliomas. The results of this study suggest the SNPs at +292 A>C, not SNPs at +191 A>C, of galectin-3 gene were associated with the tumor grade and prognosis of gliomas.